Search Results

Retreat 2023 About Program Registration Logo Contest Committee Sponsors GPCR Retreat Program < Back to schedule Interaction with the cell adhesion molecule NEGR1 affects mGluR5 cell signalling Date & Time Friday, November 3rd / 1:30 PM Abstract Coming Soon About Fabiola Ribeiro "Fabiola M. Ribeiro is an Associate Professor at the Universidade Federal de Minas Gerais (UFMG). She obtained her Ph.D. from UFMG in 2006 and, after that, she performed her postdoctorate studies at the University of Western Ontario, London, Canada, under Dr. Stephen Ferguson’s supervision. She returned to Brazil in 2010, when she founded her independent research group. Since then, Dr. Ribeiro has supervised eleven M.Sc. and six Ph.D. students, as well as five post-doctorate fellows. Nowadays, her research group comprises four undergraduates, two M.Sc., and six Ph.D. students, as well as five post-doctorate fellows and a lab technician. Dr. Ribeiro has 86 per reviewed scientific papers published in highly respected scientific journals, including 17 papers published in journals with impact higher than 7. Moreover, Dr. Ribeiro is the first or last author of 33 of these published articles. Dr. Ribeiro H factor is 28, according to Web of Science, and she is an affiliated member of the Brazilian Academy of Science. She was able to have several grants approved in Brazil and abroad, which have granted her research group a laboratory containing all the necessary equipment to perform state-of-the-art technologies. Dr. Ribeiro main scientific contributions include the study of the mechanisms involved in neurodegeneration and the characterization of neuroprotective drugs acting on the glutamatergic system. These drugs were shown to be very effective to rescue the cell death observed in a mouse model of Huntington’s disease (HD), decreasing synaptic loss and enhancing HD related memory impairment." Fabiola Ribeiro on the web Federal University of Minas Gerais, Brazil Pubmed ResearchGate Instagram Dr. GPCR Previous Event Next Event Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec Great Lakes GPCR Retreat and Club des Récepteurs à Sept Domaines Transmembranaires du Québec 22nd GPCR Retreat Sponsored by

<< Back to podcast list Dr. GPCR Podcast Strategic Partners Dr. Adriano Marchese About Dr. Adriano Marchese Adriano Marchese is a Professor of Biochemistry at the Medical College of Wisconsin. Adriano received his Bachelor of Science degree in Pharmacology in 1991 from the University of Toronto. He continued his graduate studies at the University of Toronto where he earned his MSc (1994) and Ph.D. (1998) in Pharmacology. He then moved to Thomas Jefferson University in Philadelphia, PA, for his postdoctoral training in Jeff Benovic’s laboratory studying the regulation of G protein-coupled receptor trafficking and signaling. In 2004 Adriano joined the faculty of the Department of Pharmacology at Loyola University Chicago. In 2016 he decided to move his lab to the Medical College of Wisconsin in Milwaukee, WI. Adriano’s research has contributed to our understanding of the role that ubiquitin plays in GPCR signaling and trafficking. His laboratory is interested in understanding the mechanisms that govern spatial and temporal regulation of GPCR signaling by -arrestins and post-translational modifications (PTMs), such as phosphorylation, ubiquitination, and SUMOylation. His lab has shown a role for -arrestins and PTMs in GPCR trafficking and signaling and has leveraged this knowledge to reveal the spatial and temporal requirements for GPCR activation of signaling pathways related to cell survival, proliferation, and migration. The ultimate goal of Adriano’s research is to target novel aspects of GPCR signaling for therapeutic development. Dr. Adriano Marchese on the web Twitter LinkedIn Google Scholar Website Dr. GPCR Ecosystem Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles How GPCR Collaboration Built an Innovation Engine From Pipettes to Platforms: The Evolution of GPCR Research How GPCR Spatial Signaling Sparked a Scientific Journey Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

Full Agenda Adhesion GPCR workshop 2024 CINVESTAV, Mexico City, Mexico October 23-25 Download PDF Program HERE < Back to Full Agenda Coffee Break with pastries announcement of the aGEM award Complimentary < Previous Session Next Session >

Full Agenda Adhesion GPCR workshop 2024 CINVESTAV, Mexico City, Mexico October 23-25 Download PDF Program HERE < Back to Full Agenda Departure < Previous Session Next Session >

Dr. Alex Serafini shares why pain research must start with real-world behavior and models before drilling into GPCR targets — a top-down rethink for drug discovery. << Back to podcast list Dr. GPCR Podcast Strategic Partners GPCRs and the Science Behind Pain and Recovery with Dr. Alex Serafini 1. Strategy: From Personal Pain to Scientific Purpose Dr. Alex Serafini’s entry into science wasn’t typical. Born in California, raised in Silicon Valley, and initially eyeing finance, his trajectory took a sharp turn after struggling with unresolved, chronic pain following repeated surgeries for a pilonidal cyst. "I wasn't able to get stronger pain meds because of the opioid epidemic," he recalls. That gap in care sparked a curiosity that became a career. Driven by personal experience and a desire to innovate in pain management, Alex pursued a master's in pain research at Hopkins and later an MD-PhD at Mount Sinai. His early exposure to TRPV1 channels and peripheral pain mechanisms with Dr. Mike Caterina laid the foundation. But the deeper mission? Finding answers for patients society often overlooks. Pain became more than biology — it became a personal strategy. “I started going through what I was going through… and that got me very interested in research.” — Alex Serafini 2. Decision-Making: Saying Yes to the Unorthodox Path Serafini’s journey defied traditional checklists. He joined Mount Sinai through FlexMed — bypassing the MCAT — and was torn between a career in pharma and academia. At one point, he had a job offer at Roivant (a biotech firm known for repurposing shelved compounds), but a late-stage offer into an MD-PhD program — and parental “encouragement” — rerouted his path. His approach to decision-making is pragmatic: follow impact, not orthodoxy. The decision to stay on as a postdoc in the same lab as his PhD — with Dr. Venetia Zachariou — wasn't the typical next step, but it allowed him to wrap up high-impact work and learn about PI-level grant writing, strategy, and lab management. In his words: “She let me run projects like a junior PI.” “I didn’t need to chase new techniques — I needed to finish the science that mattered.” — Alex Serafini 3. Blind Spots: The Underestimated Role of RGS Proteins in Pain Although not a self-proclaimed GPCR specialist, Serafini found himself repeatedly drawn to them, or more precisely, to RGS (Regulators of G protein Signaling) proteins. The lab’s work with RGS4 led to unexpected results: knockout mice spontaneously recovered from chronic pain after three weeks, an effect rarely observed. He points out that GPCRs—especially orphan and CNS-associated ones—are often downplayed in pain research, with most focus on ionotropic targets like NAV1.8. But Serafini believes that’s a blind spot. “We’re using outdated drugs. There are more elegant GPCR targets waiting to be explored.” The lab’s unconventional in vivo-first strategies, combined with RNA-seq and behavioral analysis, revealed nuanced roles of RGS4, RGS9, and RGSZ — not just as modulators but as potential therapeutic linchpins. “Half the time, in pain, what works in vivo doesn’t translate to clinic. We need new thinking.” — Alex Serafini 4. Failure & Frustration: From Pipettes to Pandemic Disruption The road hasn’t been smooth. From struggling to grip mice in early animal studies to thesis delays during COVID-19, Serafini's journey is marked by grit. But it’s in these friction points that new insights emerged. The pandemic disruption, for instance, led him to BSL-3 labs to study persistent pain after SARS-CoV-2 infection, revealing novel immune-neuron signaling in DRGs. He also opens up about the emotional and logistical toll of MD-PhD training. It’s an eight-year-plus haul with built-in uncertainty. However, with mentors who believed in him, especially those who shared administrative, grant-writing, and leadership skills early on, he found direction and resilience. “She [Vanna] gave me a crash course in what it’s like to be a junior PI. That changed everything.” — Alex Serafini 5. Pivoting: Redefining the Pain Research Playbook Looking ahead, Serafini’s vision is bold: build a lab that develops translational models of pain rooted in patient realities. He’s fascinated by transgenerational epigenetics — how parental pain, diet, or drug exposure can leave molecular fingerprints in offspring. He's equally focused on sex differences in pain processing and the failure of "one-size-fits-all" models in pharmacology. His advice? Learn broadly. Stay close to patients. Collaborate relentlessly. And above all, don’t be afraid to start from the phenotype and work backwards to the mechanism. That top-down approach, though less common, could help pain research finally catch up with the complexity of real-world biology. “Start from the end — from the clinic — and then build backwards.” — Alex Serafini _________ Key Takeaway Innovation in pain research won’t come from doing the same things better — it’ll come from flipping the script. Whether it’s challenging legacy targets, redefining preclinical models, or exploring the epigenetic inheritance of pain, Dr. Serafini urges the field to stay bold, patient-centered, and GPCR-aware. Keyword Cloud GPCR research community, Dr. GPCR ecosystem, GPCR drug discovery, GPCR podcast, GPCR data platform, GPCR training program, RGS4, chronic pain, epigenetics, translational models. Summary created by AI ________ About Alex Serafini Alex was born and raised in the Bay Area and received his BS/MS Neuroscience from Johns Hopkins. His master's degree was in Dr. Michael Caterina's lab studying the role of PNS chloride transporters in neuropathic pain. Upon matriculating to Mount Sinai's MD/PhD program, he joined Dr. Venetia Zachariou's lab to study the effects of chronic pain and addiction/withdrawal on the mesocorticolimbic system, focusing on transcription factor and RGS protein maladaptations, behavioral RGS protein drug "screening", and the role of SARS-CoV-2 on CNS function and sensory hypersensitivity. He aspires to become a physician-scientist, with a focus on translational in vitro and in vivo model development for studying chronic pain and affective comorbidities. Other academic interests of his include studying pharmaceutical finance & healthcare administration and developing technologies that increase healthcare access. His non-academic interests include traveling, scouting out micro-breweries, and collecting beer cans. Alex Serafini on the web LinkedIn Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles How GPCR Collaboration Built an Innovation Engine From Pipettes to Platforms: The Evolution of GPCR Research How GPCR Spatial Signaling Sparked a Scientific Journey Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

Home → Flash News → terrys corner from data to insight Published on July 14, 2025 Category Terry's Corner Pharmacology’s hidden power? The model behind the data 💡 Terry Kenakin shows how experimental snapshots can reveal much more—and how predictive frameworks guide modern drug discovery. 🟢 Built for pharmacologists building stronger pipelines and those rethinking legacy models. ✳️ https://www.terrykenakin.com #GPCR #DrGPCR #pharmacology #drugmodeling #terrykenakin Previous Next Recent Articles

<< Back to podcast list Dr. GPCR Podcast Strategic Partners Dr. Terry Kenakin About Dr. Terry Kenakin After obtaining a BSc in chemistry at the University of Alberta Edmonton Canada, Terry received his Ph.D. in Pharmacology from the University of Alberta, Department of Chemistry, Canada. Dr. Kenakin then moved to the UK, where he did a post-doctoral fellowship in University College London with Sir James Black. His next stop took him to Burroughs-Wellcome (BW) in Research Triangle Park (RTP) in North Carolina USA. After 7 years at BW, Dr. Kenakin joined Glaxo Inc in RTP where he remained for 25 years through iterations of Glaxo Inc, GlaxoWellcome , and finally GlaxoSmithKline . Since 2011, Terry works at the Department of Pharmacology at the University of North Carolina School of Medicine Chapel Hill NC. His interests are in receptor pharmacology, allosteric protein function, and drug discovery. Dr. Terry Kenakin on the web LinkedIn UNC Department of Pharmacology Amazon ResearchGate Pubmed . Dr. GPCR Ecosystem Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles How GPCR Collaboration Built an Innovation Engine From Pipettes to Platforms: The Evolution of GPCR Research How GPCR Spatial Signaling Sparked a Scientific Journey Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

Home → Flash News → What can an updated profile do for you? 🔎 Personalized content, better networking, and collaboration opportunities. Fill in the blanks—update now! ✳️Visit https://bit.ly/4fY4UHV today #gpcr #drgpcr Published on January 15, 2025 Category Dr. GPCR Profiles What can an updated profile do for you? 🔎 Personalized content, better networking, and collaboration opportunities. Fill in the blanks—update now! ✳️Visit https://bit.ly/4fY4UHV today #gpcr #drgpcr Previous Next Recent Articles

<< Back to podcast list Dr. GPCR Podcast Strategic Partners Dr. Maria Waldhoer About this episode Dr. Maria Waldhoer is originally from Austria. She earned her M.Sc. in Zoology and Neurobiology before completing a Ph.D. in Biology and Pharmacology at the University of Vienna. GPCRs led Maria to Thue W. Schwartz’s lab in Copenhagen where she completed her postdoctoral training. After working in the US and at the University in Graz in Austria, Maria worked several years at Novo Nordisk before joining InterAx Biotech in Switzerland as their Chief Scientific Officer. Even though Maria stumbled upon the GPCR field, her 20 years in both academia and in the industry working on GPCRs make her a strong and dedicated scientific leader. Dr. Maria Waldhoer on the web LinkedIn InterAx Biotech Pubmed Dr. GPCR Ecosystem Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles How GPCR Collaboration Built an Innovation Engine From Pipettes to Platforms: The Evolution of GPCR Research How GPCR Spatial Signaling Sparked a Scientific Journey Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

<< Back to podcast list Dr. GPCR Podcast Strategic Partners Martin Audet About Dr. Martin Audet Structural biologist, pharmacologist, and a professor of pharmacology at Université de Sherbrooke. He is the head of the AudetLab located at the Institute of Pharmacology of Sherbrooke and is an emerging leader in the structural biology of G Protein-Coupled Receptors and passive transporters. Strong education with a Doctor of Philosophy (Ph.D.) in biochemistry under the supervision of Michel Bouvier at Université de Montréal, followed by a Postdoctoral Fellow at Scripps Research in San Diego and the University of Southern California in Los Angeles as a member of Raymond Stevens group. Dr. Martin Audet on the web LinkedIn Twitter Sherbrooke University Google Scholar Dr. GPCR Ecosystem Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles How GPCR Collaboration Built an Innovation Engine From Pipettes to Platforms: The Evolution of GPCR Research How GPCR Spatial Signaling Sparked a Scientific Journey Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

<< Back to podcast list Dr. GPCR Podcast Strategic Partners Dr. GPCR Board About Dr. Yamina Berchiche "Dr. Yamina A. Berchiche is the founder of Dr. GPCR, an ecosystem designed to bring together stakeholders interested in using G-Protein Coupled Receptors (GPCRs) that control virtually everything in the body as drug targets. The mission of Dr. GPCR is to accelerate GPCR drug discovery by sharing the latest research and technology advances in the field and providing exposure to scientists through the Dr. GPCR podcast. Dr. Berchiche obtained her Master’s and Ph.D. in Biochemistry at the University of Montreal in Canada before training at Rockefeller University in New York and the National Institutes of Health in Bethesda, Maryland. She developed expertise over the past two decades studying structure/function relationships of GPCRs using live-cell bioluminescence resonance energy transfer (BRET). Her work focused on chemokine receptors, members of the GPCR family that control cell movement in the body." Dr. Yamina Berchiche on the web Website LinkedIn Facebook Twitter ResearchGate PubMed Google Scholar Dr. GPCR About Dr. Maria Waldhoer "I am a pharmacologist with a ~30 years background in academia and industry, working both in big pharma and biotech settings. My experience in basic research at several universities worldwide and early R&D at Novo Nordisk A/S allowed me to shape a swiss start-up company from a scientifc idea to a thriving Biotech focusing on Systems Biology & AI to accelerate the quest for novel & safer drugs on GPCRs. After a well needed break from the grind, I am now a scientific/business consultant for clients both in Academia and in the Life sciences and Healthcare industry. I am a recent convert and strong advocate for integrating mindfulness and mental wellbeing into demanding work routines." Dr. Maria Waldhoer on the web LinkedIn T witter Pubmed Dr. GPCR About Dr. JoAnn Trejo "Dr. JoAnn Trejo earned her Ph.D. at UC San Diego. She completed her postdoctoral fellowship at UC San Francisco under the guidance of Professor Shaun Coughlin where she worked on the newly discovered protease-activated GPCRs. Dr. Trejo joined the faculty in the Department of Pharmacology at the University of North Carolina in 2000 and then moved to UC San Diego School Medicine, Department of Pharmacology in 2008, where she quickly rose through the ranks to tenured professor in 2012. In 2014, she was appointed Vice-Chair of the Department of Pharmacology. The long-term goal of Dr. Trejo’s research program is to gain a thorough and mechanistic understanding of processes that control cell signaling by protease-activated receptors (PARs) and the impact on vascular inflammation and cancer progression. PARs are GPCRs that are activated through an atypical irreversible proteolytic mechanism. The precise control of PAR signaling is critical for proper temporal and spatial dynamics of signaling and appropriate cellular responses. Discovering new aspects of PAR signaling is important for increasing the fundamental knowledge of GPCR biology and for the identification of drug targets and future drug development. Dr. Trejo’s research has focused on PAR1, which has important functions in hemostasis, thrombosis, inflammation, and cancer and is an important drug target. She has made numerous important discoveries related to the mechanisms that control PAR1 signaling and closely related family members and published extensively on this topic. Dr. Trejo has been continuously funded by the NIH for >20 years and was a recipient of the prestigious American Heart Association Established Investigator Award. Her laboratory is the recognized expert on protease-activated receptors, particularly PAR1, and over the years she has discovered novel aspects of GPCR biology, acquired critical expertise, and rigorous approaches to examine PAR1 function using human cultured cells and mouse models. Dr. Trejo has presented her studies at 52 national/international meetings and 66 academic seminars across the U.S." Dr. JoAnn Trejo on the web UC San Diego Trejo Lab Wikipedia LinkedIn Google Scholar Orcid Twitter UC San Diego School of Medicine Researchgate Dr. GPCR About Anne Marie Quinn "Anne Marie Quinn has a long and varied work experience in the biocomputing and bioinformatics fields. From 1987 to 1994, they were the Director of Biocomputing at The Salk Institute, where they managed institute-wide network and biocomputing services, served on the Steering Committee of the San Diego Supercomputer Center, and provided consultation for genetic sequence analysis, molecular modeling and database searching. In 1994, they became a Bioinformatics Scientist at CuraGen Corporation. From 1995 to 2002, they worked at Yale University School of Medicine as the Bioinformatics Core Facility Manager, where they managed a technical support team providing scientific data analysis and database development services, contributed analytic support resulting in authorship of numerous scientific publications and new funding, and developed and co-taught a new course in bioinformatics for graduate students. From 2002 to 2006, they were a Senior Application Scientist at Accelrys, where they were the technical point of contact for customers assessing features of software products for drug discovery and genomic analysis, delivered technical presentations and software demonstrations to prospective customers worldwide, and developed web-based case notes, marketing seminars and product literature for scientific software. Finally, since 2006, they have been the Chief Executive Officer at Montana Molecular, LLC. Anne Marie Quinn attended Yale University from 1998 to 2000, where they earned a Master of Public Health (MPH) degree in Biostatistics and Bioinformatics. Prior to that, they obtained a Bachelor of Arts (B.A.) degree from California State University, Long Beach in 1982." Anne Marie Quinn on the web Google Scholar The Org LinkedIn Twitter Dr. GPCR Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles How GPCR Collaboration Built an Innovation Engine From Pipettes to Platforms: The Evolution of GPCR Research How GPCR Spatial Signaling Sparked a Scientific Journey Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

<< Back to podcast list Dr. GPCR Podcast Strategic Partners Dr. Arthur Christopoulos About Dr. Arthur Christopoulos " Arthur Christopoulos is the Professor of Analytical Pharmacology and the Dean of the Faculty of Pharmacy & Pharmaceutical Sciences, Monash University, Australia. His research focuses on novel paradigms of drug action at GPCRs, particularly allosteric modulation and biased agonism, and incorporates computational and mathematical modelling, structural and chemical biology, molecular and cellular pharmacology, medicinal chemistry, and preclinical models of behaviour and disease. His work has been applied to studies encompassing neurological and psychiatric disorders, cardiovascular disease, obesity, diabetes, chronic pain and addiction. He has received substantial, long-term support from international and national competitive, charitable and commercial sources, as well as being academic co-founder of three GPCR-focussed biotechnology companies. Professor Christopoulos has over 360 publications, including in leading international journals such as Nature,Science and Cell, and has delivered over 180 invited presentations. He has served on the Editorial Board of 8 international journals and was a Councillor of the International Union of Basic and Clinical Pharmacology (IUPHAR). He has also been the recipient of multiple awards, including the John J. Abel Award and the Goodman and Gilman Award from the American Society for Pharmacology and Experimental Therapeutics; the Rand Medal from the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists; the British Pharmacological Society’s Gaddum Memorial Award; the IUPHAR Sir James Black Analytical Pharmacology Lecturer; the GSK Award for Research Excellence and a Doctor of Laws (Honoris Causa) from the University of Athens. Since 2014, Clarivate Analytics have annually named him a Highly Cited Researcher in ‘Pharmacology & Toxicology’, and in 2021 also named him a Highly Cited Researcher in the additional category of ‘Biology & Biochemistry’. In 2017, he was elected a Fellow of the Australian Academy of Health and Medical Sciences, in 2018 as a Fellow of the British Pharmacological Society, and in 2021 he was elected a Fellow of the Australian Academy of Science for his seminal contributions to drug discovery. In 2023, he was elected a Fellow of the Pharmaceutical Society of Australia. " Dr. Arthur Christopoulos on the web Monash University Wikipedia Google Scholar LinkedIn Dr. GPCR AI Summary AI-generated content may be inaccurate or misleading. Always check for accuracy. Quick recap Yamina and Arthur from Monash University discussed Arthur's career journey, the importance of hard work, failure, and differentiation in academic and personal lives, and the value of international conferences. They also explored the significance of translating fundamental discoveries into clinical applications, the potential of new drugs, and the unique challenges within universities. Additionally, they discussed the importance of hiring based on differentiation, impact, and interest, the need for workforce development, and the potential of involving junior scientists and postdocs in their podcast. Lastly, they touched upon the global challenges of healthcare workforce growth, climate change, and emerging psychiatric disorders, as well as the importance of recording lectures and making pre-lesson materials available to students. Next steps - Yamina will share notes about PRISM and presentability with Arthur. - Arthur will share the story of PRISM's development and its impact on the field with Yamina. - Yamina will send an invite for a follow-up meeting with Arthur next Saturday at 9 PM. - Arthur and Yamina will prepare for the next meeting, focusing on the concept of biased agonism and discussing Dr. GPCR and the charity status. - Yamina will attempt to book Denise for a future podcast episode. Summary Arthur's Career Journey and Transition to Dean Yamina introduced Arthur to her team and discussed the use of a particular tool for meeting summaries. Arthur shared his career journey from pharmacy to becoming a professor, highlighting the influence of his mentors and the importance of his postdoctoral experience. They discussed the value of hard work, failure, and the significance of differentiation in their personal and academic lives. Towards the end, they focused on Arthur's transition to become Dean and his decision to move from Australia to the United States for a postdoctoral position. Postdoctoral Position, Scientific Dynamics, and New Drug Targets Arthur shared his decision to undertake a postdoctoral position with Nigel Bird's lab in the UK and his experiences of meeting influential figures during his time in the US. He and Yamina discussed the importance of preserving original work, the value of international conferences, and the dynamics between junior and senior scientists in a research environment. They also shared their admiration for the work of a mutual friend and discussed the history of muscarinic receptors, specifically focusing on the role of a compound that Arthur received from Fred. Lastly, they discussed the progress of new drugs targeting specific receptors for various diseases, with Arthur sharing insights on Eli Lilly's compound, Xanomeline, and the potential of M4 PAM for psychosis. Collaborative Research and Translational Approach Arthur and Yamina from Monash University discussed their collaborative approach to scientific research, emphasizing the benefits of combining their complementary skills and interests. They shared their unconventional approaches to research, including the creation of a critical mass of GPCR researchers in Australia and the initiation of a successful series of conferences. They also discussed the relocation of some university labs to facilitate collaboration and overcome the siloed department structure. Additionally, they explored the unique culture and structure of their Institute, highlighting its translational approach to research and its capacity to translate research into therapeutic commercialization. Lastly, Arthur shared three significant moments that shaped his career, including the evolution and impact of analytical pharmacology, particularly highlighting the role of Prism, a data analysis tool. Podcast Format, Team Culture, and Science Yamina and Arthur concluded their discussion and decided to take a short break. They talked about the format and length of their podcast, their professional interests, and their recent successful bid to bring Moderna to their university. They also explored the idea of starting a similar talk show format to 'Between Two Ferns', the importance of maintaining team culture, and the potential health issues among well-known scientists. Lastly, they discussed the growth and development of the Monash Institute of Pharmaceutical Sciences, the importance of knowing when to let go in scientific experiments, and the idea of a panel for building and incubating companies. Arthur's Pandemic Journey and Global Challenges Yamina and Arthur discussed Arthur's experiences during the Covid-19 pandemic, his journey as a research fellow in Australia, and his transition to the role of Dean. Arthur shared his insights into the unique grant funding system in Australia, the importance of impact in research, and the challenges of balancing administrative responsibilities with scientific pursuits. He also reflected on his personal health struggles, the growth of his university, and the faculty's successful response to the Covid crisis. The conversation also touched upon Arthur's career decisions, his scientific achievements, and the importance of learning from mistakes and self-confidence. Lastly, they discussed the global challenges of healthcare workforce growth, climate change, and emerging psychiatric disorders, as well as the importance of recording lectures and having pre-lesson materials available to students. Translating Discovery Into Clinical Application Arthur and Yamina discussed the importance of translating fundamental discoveries into clinical applications in their research, highlighting the unique opportunities presented by their location and partnerships with other institutions. They stressed the necessity of making their research goals clearer, avoiding replication, and adopting a more assertive approach in grant applications. They also emphasized the significance of fundamental discoveries, the role of biotech, and the need for efficiency and process development in university systems. The conversation highlighted ongoing challenges within universities, including resistance to change and the need to communicate expectations and protect established cultures. Hiring Process, Collaboration, and Education-Focused Initiatives Arthur emphasized the importance of differentiation, impact, and interest in their hiring process and fostering a culture of collaboration. He shared his vision of breaking down barriers and promoting education-focused initiatives, encouraging his team to be innovative and apply their skills to education. Yamina expressed a desire to learn from successful leaders and the importance of recognizing talent and matching it with the needs of a particular project. They also discussed the disruption within the pharmaceutical sector, the importance of workforce development, and the need for maintaining a healthy work-life balance. Lastly, they deliberated on involving junior scientists and postdocs in their podcast and the possibility of writing a book about their experiences in academia. Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles How GPCR Collaboration Built an Innovation Engine From Pipettes to Platforms: The Evolution of GPCR Research How GPCR Spatial Signaling Sparked a Scientific Journey Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

<< Back to podcast list Dr. GPCR Podcast Strategic Partners Dr. Neil Grimsey About Dr. Neil Grimsey " During my postdoctoral studies at USCD, I discovered a novel GPCR-dependent atypical kinase activation mechanism that drives vascular edema and inflammation. These studies shaped my future goals as an Assistant Professor in the College of Pharmacy at the University of Georgia Athens. My group studies the spatiotemporal dynamics of atypical inflammation and the control of disease progression. We have developed an array of fluorescent biosensors to map kinase activity in living cells and are exploring innovative techniques to delineate the molecular dynamics of atypical p38 and suppress kinase activation. To further define the role of atypical p38 signaling responses we are studying how atypical p38 controls the onset and pathogenesis of acute lung injury, retinal vasculopathies, and infections. " Dr. Neil Grimsey on the web LinkedIn University of Georgia Google Scholar X (Twitter) Dr. GPCR Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles How GPCR Collaboration Built an Innovation Engine From Pipettes to Platforms: The Evolution of GPCR Research How GPCR Spatial Signaling Sparked a Scientific Journey Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

Biotech founder Ajay Yekkirala shares how AI, GPCRs, and bold questions are driving next-gen pain therapeutics and drug discovery innovation. << Back to podcast list Dr. GPCR Podcast Strategic Partners From Curiosity to Breakthrough: Ajay Yekkirala on GPCR Innovation What if the key to safer, more effective drugs lies in asking the right questions — and daring to challenge what’s “not possible”? In this episode, Dr. Ajay Yekkirala shares the pivotal moments that transformed him from a curious PhD student into a GPCR drug developer and entrepreneur. Dr. Ajay Yekkirala is a GPCR pharmacologist, biotech entrepreneur, and co-founder of Superluminal Medicines, a company using machine learning to unlock new GPCR-targeted therapies. In this wide-ranging conversation, he reflects on the mentors, failures, and bold questions that shaped his journey from academia to AI-powered drug discovery. Why This Matters Translating basic GPCR science into actual medicines is broken. Ajay unpacks why—and what it takes to fix it. AI is reshaping how we understand protein dynamics , but only when driven by deep biological questions. Young scientists are hungry for alternate career paths. This episode is a playbook for thinking bigger. Innovation doesn’t happen in isolation. Ajay reveals how humility, curiosity, and collaboration fuel the future of drug discovery. What You’ll Learn in This Episode How Ajay’s failed MD/PhD application rerouted his path toward a breakthrough GPCR research career The inside story behind founding Blue Therapeutics and targeting supraspinal pain pathway What it means to “teach AI protein dynamics,” and how Superluminal is using it to predict signaling bias The entrepreneurial lessons no one tells postdocs: how to pitch, fail, and build a team Why asking “what if it can be done?” is the heart of scientific innovation Who Should Listen PhD students and postdocs exploring biotech careers GPCR scientists interested in translational innovation Biotech investors and strategic leaders seeking new drug development models Anyone curious about where AI meets molecular pharmacology About Ajay Yekkirala Dr. Ajay Yekkirala is a molecular pharmacologist, biotech founder, and scientist whose career has been defined by bold questions and even bolder moves. Originally on track to pursue an MD/PhD, a rejection letter pivoted him into a PhD program at the University of Iowa, where he studied opioid pharmacology under the legendary Dr. Philip Portoghese. That “failure” became a launchpad: Ajay later joined the lab of Dr. Clifford Woolf at Boston Children’s Hospital and Harvard Medical School, where he deepened his understanding of pain biology and began dreaming bigger. Driven by the opioid crisis and the lack of non-addictive pain treatments, Ajay co-founded Blue Therapeutics, a biotech startup focused on targeting supraspinal GPCRs for chronic pain. But he didn’t stop there. Seeing the limits of traditional drug discovery, he later co-founded Superluminal Medicines, a company using machine learning to explore GPCR structure-function relationships and predict biased signaling with precision. Ajay’s work sits at the intersection of GPCR biology, AI, and translational medicine. He’s a strong advocate for cross-disciplinary thinking, mentoring young scientists, and building companies that solve real, unmet needs in human health. His story is one of relentless curiosity, humility in the face of complexity, and an unshakable belief in science’s power to do better. Ajay Yekkirala on the web Superluminal Medicines LinkedIn Tune in now to hear how asking “what if?” led Ajay Yekkirala to reshape the future of GPCR-targeted medicine. Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles How GPCR Collaboration Built an Innovation Engine From Pipettes to Platforms: The Evolution of GPCR Research How GPCR Spatial Signaling Sparked a Scientific Journey Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

<< Back to podcast list Dr. GPCR Podcast Strategic Partners Dr. Nicholas Holliday About Dr. Nicholas Holliday After an undergraduate degree at the University of Cambridge, Nick carried out his Ph.D. at King’s College London, supported by an AJ Clark Ph.D. studentship from the British Pharmacological Society. It was these studies and subsequent postdoctoral work that led to Nick's interest in peptide messengers regulating appetite, metabolism, and the immune system, and the molecular mechanisms underlying the signaling and regulation of their GPCRs. Nick joined the University of Nottingham in 2006, where he is now Associate Professor, establishing a lab focused on G protein-coupled receptor kinetics, signaling, and trafficking and on using novel imaging techniques, such as fluorescent ligands and complementation methods, to investigate the underlying mechanisms. Since 2019, Nick has combined his university role with the leadership of Excellerate Bioscience as Chief Scientific Officer, a contract research organization specializing in molecular and cellular pharmacology. Excellerate is involved in several pre-clinical drug discovery projects for both GPCR and non-GPCR targets, using its expertise in pharmacology to deliver high-quality target validation, lead optimization, and mechanism of action studies for our clients. Dr. Nicholas Holliday on the web LinkedIn ORCID University of Nottingham Twitter Excellerate Bio Dr. GPCR Ecosystem Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles How GPCR Collaboration Built an Innovation Engine From Pipettes to Platforms: The Evolution of GPCR Research How GPCR Spatial Signaling Sparked a Scientific Journey Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

<< Back to podcast list Dr. GPCR Podcast Strategic Partners Dr. Samuel Hoare About Dr. Samuel Hoare Sam completed his Ph.D. in biochemistry, studying allosteric modulation of dopamine receptors, from the University of Kent, United Kingdom. He then moved to the National Institute of Mental Health, researching pharmacological mechanisms of Class B GPCRs as part of his postdoctoral training. Today, Sam is a pharmacology data analyst and the founder of Pharmechanics LLC , a consultancy and data analysis company supporting pharmaceutical, life science, and academic scientists in the development of new therapeutics and the understanding of receptor systems. As an industry pharmacologist, he consults with numerous pharma and biotechs in understanding and applying in vitro pharmacology data to advance drug discovery. He specializes in kinetic analysis of drug action and is known for applying binding kinetics to the development of effective therapeutics, particularly GPCR antagonists. Before founding Pharmechanics in 2016, Dr. Hoare was a pharmacology leader in the pharmaceutical industry for 15 years at Neurocrine Biosciences . He guided the in vitro biology efforts of the company for numerous drug discovery campaigns. Sam is known for demystifying complicated and newly-emerging pharmacology concepts, enabling them to be applied by project teams in optimizing new molecules. I very much enjoyed chatting with Sam about his love for GPCRs, kinetics, and decorticate the complexities of GPCR function to better target receptors. Dr. Samuel Hoare on the web Pharmechanics LLC LinkedIn Pubmed Google Scholar YouTube Dr. GPCR Member ResearchGate Dr. GPCR Ecosystem Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles How GPCR Collaboration Built an Innovation Engine From Pipettes to Platforms: The Evolution of GPCR Research How GPCR Spatial Signaling Sparked a Scientific Journey Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

<< Back to podcast list Dr. GPCR Podcast Strategic Partners Dr. John Janetzko About Dr. John Janetzko "I received my Honors BSc in Chemistry from the University of Toronto in 2011, with a focus on synthetic organic and inorganic chemistry. Following this, I pursued graduate studies in Chemistry at Harvard University. At Harvard, I worked in the labs of Drs. Daniel Kahne and Suzanne Walker studying the structure and function of the essential human enzyme, O-GlcNAc transferase (OGT). My Ph.D. work focused on understanding the mechanism of an enigmatic moonlighting function of OGT that had been described only a year earlier. Over the course of my graduate work, I gained experience with structural mass spectrometry and protein crystallography, which shaped my interest in understanding how protein dynamics are linked to function. To further develop these ideas, I joined the lab of Dr. Brian Kobilka at Stanford University at the end of 2017 for postdoctoral work. There, I’ve been working towards understanding the molecular basis of G protein-coupled receptor desensitization and trafficking. My postdoc work has made use of several techniques including various mass spectrometry approaches, single particle cryo-EM and single-molecule fluorescence spectroscopy. In July 2024 I will join the University of Colorado, Anschutz Medical Campus, as an Assistant Professor in the Department of Biochemistry and Molecular Genetics. Besides research, I am passionate about teaching, science communication and making research more inclusive and welcoming. Outside of the lab, I am an avid bike racer, an occasional cycling coach, and I enjoy spending time with my wife, son, and Bernedoodle." Dr. John Janetzko on the web Stanford University Stanford Medicine Google Scholar Personal Website ResearchGate LinkedIn Twitter Dr. GPCR AI Summary AI-generated content may be inaccurate or misleading. Always check for accuracy. Quick recap In their conversation, Yamina and John discussed crafting social media posts for John's scientific content. They also shared their respective backgrounds and future plans, with John planning to start his own lab at the University of Colorado School of Medicine. John shared his journey into science, from his interest in creative fields to his involvement in the Chemistry Olympiad and subsequent academic pursuits. The conversation also touched on the challenges of applying for academic positions in the US, the importance of adaptability in one's career, and the potential benefits of networking and mentorship. Next steps • Yamina will share ideas on supporting John's new academic position after the recording stops. • John will prioritize getting feedback from people outside his lab to structure his job seminars. Summary Social Media Post Crafting for GPCRs Yamina and John discussed crafting social media posts for John's scientific content. Yamina emphasized that the content should be kept in a PG-13 context and be scientifically related to GPCRs. John expressed his comfort in sharing his stories and agreed to follow Yamina's guidelines. They also discussed their respective backgrounds and John's future plans to start his own lab at the University of Colorado School of Medicine. John shared his journey into science and his initial interest in creative fields. John's Chemistry Olympiad Journey John shared his experiences in high school, where he developed a keen interest in advanced physics and math curriculum. He participated in various academic competitions, including math, physics, and chemistry contests. John explained that he was drawn to chemistry because it allowed him to build things in his mind and design them. He discovered the National Chemistry Olympiad and was selected to attend a provincial training camp at the University of Toronto. This led to his participation in the National Training Program in Quebec City and his selection to represent Canada at the Chemistry Olympiad in Moscow, Russia. John also mentioned his university application process, which was less stressful than the US system. Yamina shared her own experiences with applying to universities in Canada and the US. John's Chemistry Olympiad and GPCR Journey John shared his experience with the Chemistry Olympiad program, highlighting its rigorousness and advanced content that exceeds typical high school curriculums. He also reflected on his journey from his early involvement in a university chemistry lab to his current interest in graduate school, inspired by the innovative approach of using chemistry to understand and build tools for biology. Yamina sought clarification on John's involvement with GPCRs, but the transcript ended before he could respond. John's Scientific Journey and Lab Collaboration John discussed his scientific journey, starting with a project in Suzanne Walker's lab focusing on the essential mammalian protein O-GlcNAc transferase. He then moved to Dan's lab where he met Suzanne and her project. Towards the end of his PhD, John became interested in understanding how proteins operate as large macromolecular machines and decided to work on memory proteins. He chose Brian's lab due to his interest in studying conformational changes. John shared his experience of reaching out to and securing a position in Brian's lab. He detailed his initial email contact, the subsequent Skype meeting, and the in-person visit that led to his acceptance of the position. John also discussed the potential complications that arose when his then-girlfriend, now wife, was applying for residencies. Ultimately, John did join the lab after his girlfriend successfully matched at Stanford. John explained the collaborative culture in Brian's lab, where individuals are encouraged to pursue projects aligned with their interests. He shared his experience working on a project involving receptor kinases and collaborating with other postdocs in the lab to develop assays and improve the biochemistry of certain targets. The conversation emphasized the importance of diverse backgrounds and skill sets in tackling complex challenges and finding solutions. Academia vs. Industry: Career Progression Discussion Yamina and John had a detailed discussion about the prospects of staying in academia versus transitioning to biotech or industry. John shared his thoughts about the great science happening in other sectors and how the decision largely depended on the opportunities presented. Yamina agreed and sought advice from John on career progression in academia. John suggested building milestones and landmarks into a postdoc, such as applying for funding opportunities, and getting diverse feedback to effectively present work. The conversation ended with Yamina asking when a postdoc should start considering their next steps in their career. Academic Position Applications and Transition Preparation John and Yamina discussed the extensive process of applying for academic positions in the US. John suggested starting preparations a year to two years ahead due to the time needed to develop ideas, write proposals, and get feedback. They also highlighted the need for mentorship and networking in finding job opportunities. Yamina questioned whether universities adequately prepare postdocs for the transition to industry or academia, suggesting a detailed manual or guide might be helpful. Both agreed on the importance of adaptability, as unexpected situations like the Covid-19 pandemic can affect the job searching process. John shared his experiences, stating that he submitted approximately 35 to 40 applications and that the interview process is time-consuming. Career Choices and Support in Academia John shared his positive experiences from job interviews and forming friendships with colleagues at various institutions. He also discussed the challenges of choosing between job offers, including considering his wife's career, her family's location in Denver, and other factors like monetary package and colleagues. John emphasized that negotiating salary is often not possible due to strict regulations. Yamina suggested having round tables to discuss these topics. John then reflected on his career, sharing key moments of realization in his scientific work and his upcoming transition out of his lab. The conversation concluded with both John and Yamina expressing a desire to support the academic community in various ways. Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles How GPCR Collaboration Built an Innovation Engine From Pipettes to Platforms: The Evolution of GPCR Research How GPCR Spatial Signaling Sparked a Scientific Journey Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

<< Back to podcast list Dr. GPCR Podcast Strategic Partners Dr. Fiona Marshall About this episode Fiona Marshall got fascinated with GPCRs after attending a lecture on how the beta-adrenergic receptor in the heart is activated by adrenaline, during her undergraduate studies at Bath University. She then pursued her Ph.D. in neuroscience at Cambridge University. An expert in GPCR biology, Fiona published the first description of the cloning and structural requirements of the GABAB receptor. One of her career path-defining moments came when she visited Dr. Chris Tate and Dr. Richard Henderson at the Laboratory of Molecular Biology in Cambridge, UK. As a co-founder of Heptares Therapeutics , now called Sosei Heptares , a GPCR-focused drug discovery and development biotechnology company, Fiona and her team made considerable breakthroughs in the field of GPCR stabilization and structure-based drug design. Today, Dr. Marshall is the VP Head of Neuroscience Discovery and Head of Discovery UK, Global Head of Neuroscience discovery research leading teams in West Point, Boston, and London at MSD. Join me and learn more about her fascinating career trajectory. Dr. Fiona Marshall on the web LinkedIn Twitter Google Scholar MSD UK Dr. GPCR Ecosystem Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles How GPCR Collaboration Built an Innovation Engine From Pipettes to Platforms: The Evolution of GPCR Research How GPCR Spatial Signaling Sparked a Scientific Journey Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

<< Back to podcast list Dr. GPCR Podcast Strategic Partners Dr. Graeme Milligan About Dr. Graeme Milligan Professor Graeme Milligan is Gardiner Professor of Biochemistry, Dean of Research, and Deputy Head of the College of Medical, Veterinary, and Life Sciences at the University of Glasgow. His main research group centers on the function, structure, and regulation of G protein-coupled receptors (GPCRs) and their interacting proteins. His experience also includes translating knowledge generated into the selection of targets, screening, and identification of small molecule regulators of these proteins, and progressing such ligands in drug development programs. Prof. Milligan has published more than 550 peer-reviewed articles and his research has been cited more than 35,000 times. He was elected to the Fellowship of the Royal Society of Edinburgh in 1998 and to the Fellowship of the Academy of Medical Sciences in 2016. Prof. Milligan is the co-founder of both Caldan Therapeutics (2015) which discovers novel therapeutics for metabolic diseases including Type 2 Diabetes and other indications including non-alcoholic steatohepatitis (NASH) and inflammatory diseases and Keltic Pharma Therapeutics (2020) which is developing new treatments for malaria. Dr. Graeme Milligan on the web University of Glasgow ResearchGate PubMed Orcid Google Scholar LinkedIn Dr. GPCR Ecosystem Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles How GPCR Collaboration Built an Innovation Engine From Pipettes to Platforms: The Evolution of GPCR Research How GPCR Spatial Signaling Sparked a Scientific Journey Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

<< Back to podcast list Dr. GPCR Podcast Strategic Partners Self-Learning, Collaboration, and Delegation in Science with Dr. Badr Sokrat About Dr. Badr Sokrat " After completing my undergraduate studies with an internship in the laboratory of Dr. Christian Baron studying bacterial secretion systems, I joined the molecular pharmacology laboratory of Dr. Michel Bouvier at the University of Montreal. There, I completed a PhD in biochemistry exploring the non-canonical functions and possible novel mechanisms of regulation of β-arrestin following GPCR activation. Among other projects, I studied the role of β-arrestin in G protein trafficking, the impact of GPCR ubiquitination on signaling and β-arrestin functions, and the characterization of novel β-arrestin interactors. At the end of 2023, I joined the research group of Dr. Nigel Bunnett at the NYU Pain Research Center as a postdoctoral researcher. My current research focuses on investigating GPCR signaling and trafficking in the context of inflammation and chronic pain. I am particularly interested in spatial signaling bias or how GPCRs can redistribute to different subcellular compartments to trigger distinct signaling events. " Dr. Badr Sokrat on the web PubMed ResearchGate LinkedIn Dr. GPCR AI Summary AI-generated content may be inaccurate or misleading. Always check for accuracy. Quick Recap Yamina and Badr discussed their backgrounds in science, their experiences in education, and the challenges of competition and mental health in their home province of Quebec. They also discussed Badr's career trajectory, the importance of self-learning, collaboration, and delegation in scientific research, and the need for a well-organized lab manager in their global scientific team. Lastly, they highlighted the challenges scientists face in academia and industry, the importance of projection and careful communication, and the potential for future collaboration. Next Steps Badr will continue focusing his research on GPCRs involved in pain and inflammation during his postdoc at NYU. Yamina and Badr will create a virtual genealogical tree mapping the connections between researchers in the GPCR field. Yamina will continue to develop and manage the Dr. GPCR University podcast, focusing on collaboration and learning opportunities for the GPCR community. Yamina will balance her scientific work with personal interests and activities to maintain a healthy work-life balance. Summary Podcast Recording and Science Backgrounds Yamina and Badr discussed recording their podcast with Samary Eye, who made a humorous error in transcribing "Edmond" as "agendie". They then shared their backgrounds and interests in science, with Badr recounting his journey from struggling with math in an engineering physics degree to excelling in biology and obtaining a Master’s degree in biochemistry. Badr worked in various science labs, including Dr. Christian Badr’s and Dr. Philip Woozab’s, focusing on bacterial secretion systems, GPCRs, and bioinformatics. Yamina, who also attended the University of Montreal, confirmed her interest in science and mentioned their shared passion for the subject. Education, Competition, and Mental Health Discussion Badr and Yamina shared their experiences about their education, with Yamina sharing her struggles during her first trimester in college and her eventual success due to the support of a theater group and a good teacher. They both discussed the intense competition in their home province, Quebec, and its impact on students' mental health and university admission prospects. They also talked about the negative aspects of this competition, such as students putting others down, and how it can be toxic. Lastly, Badr shared his transition into the field of GPCRs.. Badr recounted Badr's Journey, Multiplexing Assays, and Collaboration Badr shared his learning process and early tasks at Michelle’s lab, which involved creating stable cell lines and identifying potential protein interactions. He described a significant moment when he confirmed a previously uncertain interaction, underscoring the importance of confidence and motivation in scientific discoveries. Yamina emphasized the potential of multiplexing assays in expanding the scope of scientific exploration and finding new protein interactions. They also discussed the concept of serendipity in scientific research, illustrating with examples of Kathleen Curran and her father. Lastly, they concurred on the collaborative nature of the scientific community, where scientists build upon each other's work. Badr's Postdoc Plans and GPCR Research Yamina and Badr discussed Badr’s career trajectory and his decision to pursue a postdoc abroad after his PhD. Badr shared his passion for GPCR signalling and regulation, specifically in the context of pain and inflammation, and how his PhD research on non-canonical GPCR roles laid the foundation for his postdoc work. He also explained his strategy for finding a suitable postdoc lab, which involved reaching out to labs whose recent research aligned with his interests. Lastly, Badr emphasized the importance of choosing a city one would like to live in for several years when deciding on a postdoc position. Badr’s Journey to Overcoming Confidence Fluctuations Badr shared his journey of overcoming fluctuating confidence levels during his PhD journey, emphasizing the importance of viewing failures as valuable learning opportunities. He highlighted that he had to regain his confidence after a period of three failed experiments. Yamina expressed interest in understanding how Badr’s experiences influenced his current role, and Badr stressed the need for individuals to develop challenges outside of their work environment to foster greater confidence. Additionally, they both agreed on the importance of mentorship in building confidence, with Yamina sharing her positive experience of being advised by her supervisor, Nikolaos. Self-Learning, Collaboration, and Delegation in Science Badr and Yamina discussed the importance of self-learning and scientific confidence in managing projects and conducting experiments. They highlighted the significance of collaboration and delegation in scientific research, noting that knowing when to ask for help and when to delegate tasks can lead to more efficient and successful results. Yamina shared her experiences of starting a project independently and then delegating tasks, while Badr shared his plans for his current project, which involved learning certain techniques himself and delegating others to colleagues. They both agreed on the value of these strategies. Yamina’s Podcast Journey and Career Advice Yamina discussed how her podcast on chemokine ligands led to new collaborations and published work. She emphasized preparation and understanding guests’ backgrounds for engaging interviews. Yamina shared her experiences at Rockefeller, where she studied chemical receptors. She aims for Dr. GPCR to serve as a global hub for the GPCR community. Badr expressed interest in broadening his skills beyond the lab, such as project management and effective communication. Yamina advised him to consider career options after his postdoc and adapt to different systems. She highlighted the importance of learning behind-the-scenes skills and staying informed through resources like GPCR news. Improving Scientific Communication and Support Yamina and Badr discussed the need for a well-organized lab manager to facilitate communication within their global scientific team and ensure scientists could focus on their research. They identified the challenges scientists, particularly students and researchers, face, such as imposter syndrome, constant pressure from administrative tasks, and difficulties in maintaining a work-life balance. Yamina and Badr agreed on the importance of individuals struggling with imposter syndrome learning to set aside their fears and doubts to move forward. They also highlighted the benefits of maintaining a supportive network and engaging in non-lab activities for mental processing and relaxation. Academia and Industry Strategies Discussed Yamina and Badr discussed the challenges and strategies of a scientist in academia and industry. Yamina highlighted the need to project a certain presence and balance one’s actions against others in the field. She also mentioned the importance of careful communication, especially when working with a boss who has a different approach. Badr agreed to reach out for a future collaboration, and they discussed the possibility of meeting in Boston. Yamina committed to sending her contact details to Badr. Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles How GPCR Collaboration Built an Innovation Engine From Pipettes to Platforms: The Evolution of GPCR Research How GPCR Spatial Signaling Sparked a Scientific Journey Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

<< Back to podcast list Dr. GPCR Podcast Strategic Partners Dr. Matthew Eddy About Dr. Matthew Eddy Matthew Eddy earned his BA in Chemistry from Oberlin College, where he trained with solid-state NMR expert Professor Manish Mehta . He then earned his Ph.D. in physical chemistry from the Massachusetts Institute of Technology, training under the mentorship of Prof. Robert Griffin . Following this, Dr. Eddy began learning and investigating human GPCRs while training in the laboratories of Professors Raymond Stevens and Kurt Wüthrich at The Scripps Research Institute. Dr. Matthew Eddy on the web Website Dr. GPCR Ecosystem Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles How GPCR Collaboration Built an Innovation Engine From Pipettes to Platforms: The Evolution of GPCR Research How GPCR Spatial Signaling Sparked a Scientific Journey Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

<< Back to podcast list Dr. GPCR Podcast Strategic Partners Dr. Ilana Kotliar About Dr. Ilana Kotliar "Ilana Kotliar is a postdoctoral associate in the lab of Tom Sakmar at The Rockefeller University, where she just recently defended her PhD thesis. Ilana uses chemical biology-based methods to study the regulation and protein-protein interactions of GPCRs and a small family of accessory proteins called RAMPs. Ilana’s research is multi-disciplinary and involves a close collaboration with proteomics experts at The Science for Life Laboratory in Sweden. She is a recipient of the prestigious Women in Entrepreneurship Award, an NIH T32 Training Grant, and two Nicholson Fellowships. Outside of the lab, Ilana is a leader within her community, spearheading several outreach initiatives including a global mentoring initiative that matches graduate student mentors to PhD applicants. Ilana graduated Summa cum laude from Cornell University, where she studied Chemistry and Chemical Biology and was recognized as a Merrill Presidential Scholar." Dr. Ilana Kotliar on the web Google Scholar LinkedIn Twitter Dr. GPCR Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles How GPCR Collaboration Built an Innovation Engine From Pipettes to Platforms: The Evolution of GPCR Research How GPCR Spatial Signaling Sparked a Scientific Journey Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

Home → Flash News → The registration deadline for the 1-day workshop “The Practical Assessment of Signaling Bias” is TOMORROW! ⏰ Save your spot in a class with the Master of Pharmacology Dr. Terry Kenakin, and get 25% off with your Premium Membership. An advanced lecture, hands-on exercises, one private call with the professor, and more! ✳️Click here https://www.ecosystem.drgpcr.com/event-details-registration/the-practical-assessment-of-signaling-bias #gpcr #drgpcr Published on February 17, 2025 Category Dr. GPCR Courses The registration deadline for the 1-day workshop “The Practical Assessment of Signaling Bias” is TOMORROW! ⏰ Save your spot in a class with the Master of Pharmacology Dr. Terry Kenakin, and get 25% off with your Premium Membership. An advanced lecture, hands-on exercises, one private call with the professor, and more! ✳️Click here https://www.ecosystem.drgpcr.com/event-details-registration/the-practical-assessment-of-signaling-bias #gpcr #drgpcr Previous Next Recent Articles

Sokhom Pin shares how he built a biotech career around GPCRs, designed a custom PhD path, and led teams through empowerment and purpose. << Back to podcast list Dr. GPCR Podcast Strategic Partners GPCR Pharmacology, Career Twists & Serendipity with Sokhom Pin 1. From the Bench to the Boardroom Sokhom Pin’s story begins not with prestige or privilege but with grit and commitment. From his early work as a technician at Johns Hopkins Hospital to leading biology at Servo Therapeutics, Sokhom’s journey is rooted in practicality and purpose. He shares: "All my industry experience has been GPCR-focused." Starting at DuPont, then BMS, Novartis, and eventually founding in vitro pharmacology departments, Sokhom always stayed anchored to G protein-coupled receptors (GPCRs). 2. Family First, Always The decision to shift from academia to industry wasn’t driven by disillusionment—it was about responsibility. “I had two kids and realized I just couldn’t support a family on a technician’s salary.” This pragmatic decision led him to high-throughput screening at DuPont, proving that scientific ambition doesn’t have to mean sacrificing personal commitments. 3. Falling in Love with GPCRs GPCR pharmacology captured his scientific curiosity. Sokhom recalls how binding assays at BMS introduced him to the depth and complexity of receptor pharmacology: “It’s not just about IC50s. There’s allosterism, receptor desensitization… it opened a whole new world.” This moment became pivotal—transforming technical proficiency into passion. 4. Designing a Non-Traditional PhD While working full-time, Sokhom architected a one-of-a-kind PhD program between BMS and UConn. “I had to find a way. I wanted a PhD, but I couldn’t quit my job.” Through strategic coordination, he executed a PhD entirely in the industry setting—efficient, targeted, and rooted in real-world projects like CGRP receptor antagonists. 5. From Scientist to Leader At Alkermes, Sokhom took his first leadership role and finally experienced the power of empowerment . “That’s the moment that changed my entire career. I was trusted to build a team from scratch.” He focused on culture—ensuring passion and purpose drove performance. 6. The Power of the Right Culture Whether it was Alkermes or Cerevel, Sokhom emphasized that team culture trumps individual genius . “It doesn’t matter how brilliant someone is—if they’re toxic, I don’t want them on the team.” He built what others called the “happiest team at Alkermes,” showing that joy and scientific rigor aren’t mutually exclusive. 7. Network or Miss Out One powerful shift came when Sokhom leaned into networking—despite being an introvert. “I changed from being an extreme introvert to someone who thrives on connection.” His story underscores how something as simple as forwarding a resume or reaching out for coffee can change careers. 8. The Lifecycle of GPCR Popularity Sokhom has witnessed the waves of scientific fashion: “There was a time GPCRs were hot, then ignored. Now they’re back.” His unwavering dedication through these cycles became an asset—many others shifted focus, leaving a smaller, highly skilled group of GPCR specialists. 9. Lessons from Molecules and Mentors He draws inspiration from scientific complexity and colleagues like Arthur Christopoulos and Terry Kenakin. “What fascinates me is how the same molecule behaves differently depending on one amino acid.” He blends classical receptor pharmacology with biosensor technology, always adapting to new tools and insights. 10. Don’t Let Weakness Define You The episode ends with a deeply human reflection: “Don’t let your weakness define your life. Overcome it. I used to sweat thinking about presentations. Now I love them.” Whether it’s networking, leadership, or technical mastery, Sokhom’s message is clear: keep evolving, and don’t settle. ________ Key Takeaway Sokhom Pin's journey is a masterclass in scientific persistence , non-traditional success , and values-driven leadership . For any scientist navigating career uncertainty—his story is both roadmap and inspiration. Keyword Cloud GPCR research community , Dr. GPCR ecosystem , GPCR scientist network , GPCR drug discovery , GPCR training program , GPCR online course , G protein-coupled receptors , GPCR podcast , GPCR webinar series , GPCR data platform Summary created by AI ________ About Sokhom Pin Sokhom Pin is a receptor pharmacologist with over 20 years of drug discovery research in the pharmaceutical industry, where he works mainly on GPCRs as therapeutic targets. He is passionate about mechanistic profiling of therapeutic molecules as well as drug discovery in general. Outside of science Sokhom enjoys outdoor activities such as hiking, boating, fishing, and biking. Sokhom Pin on the web LinkedIn Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles How GPCR Collaboration Built an Innovation Engine From Pipettes to Platforms: The Evolution of GPCR Research How GPCR Spatial Signaling Sparked a Scientific Journey Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

<< Back to podcast list Dr. GPCR Podcast Strategic Partners Mark Schmeizl About Mark Schmeizl Mark leverages 30 years in various life science laboratories & commercial roles with his network of VC & PE contacts to help senior-level life science executives identify new opportunities. He has successfully built numerous global life science, leadership teams, & works closely with both clients & candidates to understand their unique needs & culture. Mark believes professional placement should be about matching talented people with companies where they will thrive, “when the match is right, the results are astonishing.” Dr. Mark Schmeizl on the web Website LinkedIn Dr. GPCR Ecosystem Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles How GPCR Collaboration Built an Innovation Engine From Pipettes to Platforms: The Evolution of GPCR Research How GPCR Spatial Signaling Sparked a Scientific Journey Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

Home → Flash News → Dr. Maria Majellaro perfected her focaccia recipe. Then, with Celtarys, the team did the same for ligand-linker-fluorophore chemistry. It’s not just culinary precision, it’s a metaphor for drug discovery done right. In Ep. 168, she shares how Celtarys went from a thesis idea to a biotech reality. Meet Dr.GPCR’s new partner: Celtarys 🙌 👉 See what they’re cooking up now: Ep 168 with Dr. Maria Majellaro from Celtarys #GPCRresearchCommunity #DrGPCR #StartupScience #BiotechFounders #GPCRscientistNetwork Published on June 12, 2025 Category Dr. GPCR Podcast Dr. Maria Majellaro perfected her focaccia recipe. Then, with Celtarys, the team did the same for ligand-linker-fluorophore chemistry. It’s not just culinary precision, it’s a metaphor for drug discovery done right. In Ep. 168, she shares how Celtarys went from a thesis idea to a biotech reality. Meet Dr.GPCR’s new partner: Celtarys 🙌 👉 See what they’re cooking up now: Ep 168 with Dr. Maria Majellaro from Celtarys #GPCRresearchCommunity #DrGPCR #StartupScience #BiotechFounders #GPCRscientistNetwork Previous Next Recent Articles

Home → Flash News → What if you could map GPCR-RAMP interactions across the entire superfamily in a single experiment? That’s precisely what Dr. Kotliar from the Sakmar lab made possible! In Ep.167 of the Dr. GPCR Podcast, we chat with Drs. Tom Sakmar and Ilana Kotliar about how their lab developed: A multiplexed Luminex assay to screen hundreds of interactions at once A 220-clone DUET-tagged GPCR library, available on Addgene An online interface to search GPCR-RAMP data and antibody validations This is open-access science at its best, built for the GPCR research community. ✳️ Listen to the episode: Ep 167 with Drs. Tom Sakmar & Ilana Kotliar #GPCRresearch #DrGPCRecosystem #GPCRdrugdiscovery #GPCRtrainingprogram #GPCRpodcast Published on May 27, 2025 Category Dr. GPCR Podcast What if you could map GPCR-RAMP interactions across the entire superfamily in a single experiment? That’s precisely what Dr. Kotliar from the Sakmar lab made possible! In Ep.167 of the Dr. GPCR Podcast, we chat with Drs. Tom Sakmar and Ilana Kotliar about how their lab developed: A multiplexed Luminex assay to screen hundreds of interactions at once A 220-clone DUET-tagged GPCR library, available on Addgene An online interface to search GPCR-RAMP data and antibody validations This is open-access science at its best, built for the GPCR research community. ✳️ Listen to the episode: Ep 167 with Drs. Tom Sakmar & Ilana Kotliar #GPCRresearch #DrGPCRecosystem #GPCRdrugdiscovery #GPCRtrainingprogram #GPCRpodcast Previous Next Recent Articles

<< Back to podcast list Dr. GPCR Podcast Strategic Partners Dr. Kathleen Caron About Kathleen M. Caron Kathleen M. Caron, Ph.D. is the Frederik L. Eldridge Distinguished Professor and Chair of the Department of Cell Biology & Physiology at The University of North Carolina at Chapel Hill—a large, interdisciplinary basic science department currently ranked 1st in the Nation in NIH funding. Dr. Caron received a BS in Biology and BA in Philosophy at Emory University and a PhD at Duke University while training with Dr. Keith Parker to elucidate the role of steroidogenesis in regulating sexual determination and adrenal and gonadal development using genetic mouse models. She pursued postdoctoral training with Nobel Laureate Dr. Oliver Smithies at UNC-CH, where she was the first to discover the essential role of adrenomedullin peptide for embryonic survival. With a special emphasis on G protein coupled receptors and receptor activity modifying proteins in vascular biology, the Caron laboratory has gained valuable insights into the genetic basis and pathophysiology of lymphatic vascular disease, preeclampsia and sex-dependent cardiovascular disease. Dr. Caron has received numerous awards including a Burroughs Wellcome Fund Career Award in the Biomedical Sciences, an Established Investigator Award and an Innovator Award from the American Heart Association, a Jefferson Pilot Award in Biomedical Sciences and a UNC-CH Mentoring Award. She currently serves as Associate Editor of Physiological Reviews; the #1 ranked journal in Physiology (IF 46.5). Dr. Caron is also past Associate Editor at JCI and served as the inaugural Associate Editor at ACS-Pharmacology and Translational Science. Dr. Caron currently holds multiple scientific advisory roles in academia, industry and the National Institutes of Health. Kathleen M. Caron on the web Lab Website Twitter Pubmed Google Scholar Orcid Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles How GPCR Collaboration Built an Innovation Engine From Pipettes to Platforms: The Evolution of GPCR Research How GPCR Spatial Signaling Sparked a Scientific Journey Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

<< Back to podcast list Dr. GPCR Podcast Strategic Partners Empowering Drug Discovery for the GPCR Community with Dr. Justin English About Dr. Justin English "Dr. English earned his PhD at UNC Chapel Hill in the laboratory of Dr. Henrik Dohlman and performed his postdoctoral work with Dr. Bryan Roth at the same University. We moved to Salt Lake City, Utah in 2020 to begin his own laboratory in the Department of Biochemistry at the University of Utah School of Medicine. His lab focuses on developing and innovating technologies to solve broad questions in pharmacology, with a specific focus on G-protein coupled receptor signaling and biology." Dr. Justin English on the web The English Lab University of Utah Google Scholar LinkedIn Dr. GPCR Enjoying the Dr. GPCR Podcast? Leave a Review. Leave a quick review to help more scientists find the show—and help us keep improving every episode. It takes <60 seconds and makes a big difference. ★ Review on Apple Podcasts ★ Rate on Spotify ✉️ Send feedback to the team Recent Podcast Articles How GPCR Collaboration Built an Innovation Engine From Pipettes to Platforms: The Evolution of GPCR Research How GPCR Spatial Signaling Sparked a Scientific Journey Thanks for listening to this podcast episode Follow us on your favorite Podcast Player << Previous Podcast Episode Next Podcast Episode >>

Full Agenda Adhesion GPCR workshop 2024 CINVESTAV, Mexico City, Mexico October 23-25 Download PDF Program HERE < Back to Full Agenda Leaving for City Center Coming Soon < Previous Session Next Session >